TP53 and central nervous system cancer: This is similar to human patients where gliomas represent 24% of all primary CNS tumors with an incidence of approximately 20 per 100,000 [3] Extensive analysis of gliomas in humans has defined commonly disrupted pathways involving the receptor tyrosine kinases/PI3K/RAS, TP53 and RB1 pathways [10,11].